Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | CDK4 | P11802 | 1/20 | 0.51 |
| ▸ | CCND1 | P24385 | 1/20 | 0.51 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | MPO | P05164 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.45 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.45 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.44 |
| ▸ | CAPN2 | P17655 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30622613 | 1.00 | KDM4E (0.55) | KDM4ECDK4CCND1MAPK14TSHR | |
| SCHEMBL24243751 | 0.86 | KDM4E (0.50) | KDM4ECDK4CCND1TSHRMPO | |
| SCHEMBL207031 | 0.85 | KDM4E (0.57) | KDM4ECDK4CCND1TSHRMPO | |
| SCHEMBL25311099 | 0.84 | KDM4E (0.48) | KDM4ECDK4CCND1TSHRMPO | |
| SCHEMBL24243752 | 0.84 | HTR2A (0.48) | KDM4ECDK4CCND1TSHRMPO | |
| SCHEMBL30515270 | 0.84 | KDM4E (0.48) | KDM4ECDK4CCND1TSHRMPO | |
| SCHEMBL5176370 | 0.82 | HPGD (0.46) | ALDH1A1HPGD | |
| SCHEMBL7476741 | 0.82 | NR4A2 (0.61) | MTNR1AMTNR1BSLC6A4GPR84SMN1; SMN2 | |
| SCHEMBL31077764 | 0.82 | MAPK14 (0.45) | MAPK14GPR84 | |
| SCHEMBL25748812 | 0.82 | MAPK14 (0.45) | MAPK14GPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260055059-A1 | METHODS OF TREATING MOOD DISORDERS | GILGAMESH PHARMACEUTICALS, INC. (US) | 2026-02-26 | — | — | US | disclosed |
| US-20250353827-A1 | INDOLINE DERIVATIVES AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | MINDSET PHARMA INC (CA) | 2025-11-20 | — | — | US | disclosed |
| EP-4511360-A1 | INDOLINE DERIVATIVES AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | Mindset Pharma Inc. (CA) | 2025-02-26 | — | — | EP | disclosed |
| US-20240351983-A1 | METHODS OF TREATING MOOD DISORDERS | GILGAMESH PHARMACEUTICALS, INC. (US) | 2024-10-24 | — | — | US | disclosed |
| US-20240317683-A1 | METHODS OF TREATING MOOD DISORDERS | GILGAMESH PHARMACEUTICALS, INC. (US) | 2024-09-26 | — | — | US | disclosed |
| WO-2023201421-A1 | INDOLINE DERIVATIVES AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | MINDSET PHARMA INC. (CA) | 2023-10-26 | — | — | WO | disclosed |
| US-11440879-B2 | Methods of treating mood disorders | GILGAMESH PHARMACEUTICALS, INC. (US) | 2022-09-13 | — | — | US | disclosed |
| US-20220241243-A1 | METHODS OF TREATING MOOD DISORDERS | GILGAMESH PHARMACEUTICALS, INC. | 2022-08-04 | — | — | US | disclosed |
| US-20220241243-A1 | METHODS OF TREATING MOOD DISORDERS | GILGAMESH PHARMACEUTICALS, INC. | 2022-08-04 | — | — | US | disclosed |
| US-20220041551-A1 | METHODS OF TREATING MOOD DISORDERS | GILGAMESH PHARMACEUTICALS, INC. (US) | 2022-02-10 | — | — | US | disclosed |
| US-20220041551-A1 | METHODS OF TREATING MOOD DISORDERS | GILGAMESH PHARMACEUTICALS, INC. (US) | 2022-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11440879-B2 | Methods of treating mood disorders | GRIN2C, GRIN2A, TPH2 | KDM4E 1141/4885CDK4 1444/4885CCND1 4076/4885 |
| US-20240351983-A1 | METHODS OF TREATING MOOD DISORDERS | GRIN2C, GRIN2A, TPH2 | KDM4E 1141/4885CDK4 1444/4885CCND1 4076/4885 |
| US-20220041551-A1 | METHODS OF TREATING MOOD DISORDERS | GRIN2C, GRIN2A, TPH2 | KDM4E 1141/4885CDK4 1444/4885CCND1 4076/4885 |
| US-20250353827-A1 | INDOLINE DERIVATIVES AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | TPH1, TPH2, HTR5A | KDM4E 4395/4885CDK4 3231/4885CCND1 1434/4885 |
| US-20260055059-A1 | METHODS OF TREATING MOOD DISORDERS | SDHB, SDHA, SORD | KDM4E 1164/4885CDK4 1778/4885CCND1 1089/4885 |
| US-20220241243-A1 | METHODS OF TREATING MOOD DISORDERS | GRIN2C, GRIN2A, TPH2 | KDM4E 1141/4885CDK4 1444/4885CCND1 4076/4885 |
| US-20240317683-A1 | METHODS OF TREATING MOOD DISORDERS | GRIN2C, GRIN2A, TPH2 | KDM4E 1141/4885CDK4 1444/4885CCND1 4076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.